bioMérieux
A global leader in in vitro diagnostics for clinical and industrial applications.
BIM | PA
Overview
Corporate Details
- ISIN(s):
- FR0013280286 (+13 more)
- LEI:
- 549300AK8Y0LBIQ4T071
- Country:
- France
- Address:
- 376 CHE DE L'ORME, 69280 MARCY-L'ETOILE
- Website:
- https://www.biomerieux.com/
- Sector:
- Manufacturing
Description
bioMérieux is a global leader in the field of in vitro diagnostics, providing solutions that determine the source of disease and contamination. The company develops and manufactures diagnostic systems, reagents, and software for both clinical and industrial applications. In the clinical sector, its products are used for diagnosing infectious diseases, managing sepsis, combating antimicrobial resistance, and supporting cancer screening and cardiovascular emergencies. For industrial markets, bioMérieux offers microbiological control solutions to ensure the safety and quality of agri-food, pharmaceutical, and cosmetic products. These technologies provide rapid and reliable data to help healthcare professionals and industrial quality control managers make critical decisions that improve patient outcomes and ensure consumer safety.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Type / Size | Actions | |
|---|---|---|---|---|---|
| 2023-10-13 07:02 |
bioMérieux announces CE-marking of VIDAS® TBI (GFAP, UCH-L1), a test for improv…
|
English | PDF • 239.4 KB | ||
| 2023-10-13 07:02 |
bioMérieux annonce le marquage CE du test VIDAS® TBI (GFAP, UCH-L1), pour une m…
|
French | PDF • 245.3 KB | ||
| 2023-10-05 14:15 |
Septembre 2023 - Déclaration sur le nombre d'actions composant le capital socia…
|
French | PDF • 105.4 KB | ||
| 2023-09-22 07:01 |
bioMérieux submits Dual 510(k) and CLIA-waiver application to FDA for the BIO…
|
English | PDF • 227.4 KB | ||
| 2023-09-22 07:01 |
bioMérieux dépose une double demande d'agrément 510(k) et de dérogation CLIA au…
|
French | PDF • 231.3 KB | ||
| 2023-09-05 11:36 |
Août 2023 - Déclaration sur le nombre d'actions composant le capital social et …
|
French | PDF • 106.0 KB | ||
| 2023-09-04 08:30 |
Rapport Financier Semestriel 2023
|
French | PDF • 2.7 MB | ||
| 2023-09-04 08:30 |
Rapport Financier Semestriel 2023
|
French | PDF • 2.8 MB | ||
| 2023-09-01 07:01 |
bioMérieux – First-Half 2023 Results
|
English | PDF • 365.1 KB | ||
| 2023-09-01 07:01 |
bioMérieux?–?Résultats semestriels au 30 juin 2023
|
French | PDF • 451.1 KB | ||
| 2023-08-04 16:33 |
Juillet 2023 - Déclaration sur le nombre d’actions composant le capital social …
|
French | PDF • 105.3 KB | ||
| 2023-07-04 15:38 |
Juin 2023 - Déclaration sur le nombre d'actions composant le capital social et …
|
French | PDF • 105.9 KB | ||
| 2023-06-27 18:31 |
bioMérieux’s Executive Committee evolves: Jennifer Zinn appointed Executive Vic…
|
English | PDF • 233.1 KB | ||
| 2023-06-27 18:31 |
Évolution du Comité de Direction de bioMérieux : Jennifer Zinn est nommée Direc…
|
French | PDF • 234.3 KB | ||
| 2023-06-14 07:26 |
bioMérieux evolves its governance: Alexandre Mérieux becomes Executive Chairman…
|
English | PDF • 225.1 KB |
Automate Your Workflow. Get a real-time feed of all bioMérieux filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for bioMérieux
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for bioMérieux via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| 2023-09-04 | N/A | Other | Sell | 1,432 | 137,517.82 EUR |
| 2023-09-04 | N/A | Other | Sell | 1,253 | 120,328.10 EUR |
| 2023-09-01 | N/A | Other | Other | 2,900 | N/A |
| 2023-06-23 | N/A | Other | Other | 323 | 24,971.13 EUR |
| 2023-06-23 | N/A | Other | Buy | 323 | 24,971.13 EUR |
| 2023-06-23 | N/A | Other | Buy | 300 | 23,193.00 EUR |
| 2023-06-23 | N/A | Other | Buy | 25 | 1,932.75 EUR |
| 2023-03-23 | N/A | Other | Sell | 16,500 | 1,650,415.80 EUR |
Peer Companies
